Terodiline, an antispasmodic agent, blocks hERG current with the IC50 of 375 nM.Terodiline has both anticholinergic and calcium antagonist properties, and effectively reduces abnormal bladder contractions caused by detrusor instability.Terodiline can be used for the research of urinary incontinence[1][2].
World Health Organization (WHO)
Terodiline, an anticholinergic and calcium-channel blocking
agent, was first introduced into medicine in the mid 1960s for the treatment of
angina pectoris. In 1986, it was registered for the indication of urinary
incontinence. In 1991, its use in urinary incontinence was reported to be
associated with severe cardiac arrhythmias. This led to a temporary withdrawal in a
few Member States in 1991, followed by a final withdrawal by the manufacturer in
1992.
